GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Granules India Ltd (NSE:GRANULES) » Definitions » EV-to-EBIT

Granules India (NSE:GRANULES) EV-to-EBIT : 17.34 (As of May. 24, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Granules India EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Granules India's Enterprise Value is ₹113,258 Mil. Granules India's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹6,531 Mil. Therefore, Granules India's EV-to-EBIT for today is 17.34.

The historical rank and industry rank for Granules India's EV-to-EBIT or its related term are showing as below:

NSE:GRANULES' s EV-to-EBIT Range Over the Past 10 Years
Min: 3.63   Med: 12.38   Max: 20.36
Current: 17.35

During the past 13 years, the highest EV-to-EBIT of Granules India was 20.36. The lowest was 3.63. And the median was 12.38.

NSE:GRANULES's EV-to-EBIT is ranked worse than
51.19% of 670 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs NSE:GRANULES: 17.35

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Granules India's Enterprise Value for the quarter that ended in Mar. 2024 was ₹113,513 Mil. Granules India's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹6,531 Mil. Granules India's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 5.75%.


Granules India EV-to-EBIT Historical Data

The historical data trend for Granules India's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Granules India EV-to-EBIT Chart

Granules India Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.11 11.19 14.58 10.61 17.37

Granules India Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.61 10.92 15.67 15.56 17.37

Competitive Comparison of Granules India's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Granules India's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Granules India's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Granules India's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Granules India's EV-to-EBIT falls into.



Granules India EV-to-EBIT Calculation

Granules India's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=113258.176/6530.5
=17.34

Granules India's current Enterprise Value is ₹113,258 Mil.
Granules India's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,531 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Granules India  (NSE:GRANULES) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Granules India's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=6530.5/113512.78535
=5.75 %

Granules India's Enterprise Value for the quarter that ended in Mar. 2024 was ₹113,513 Mil.
Granules India's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,531 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Granules India EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Granules India's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Granules India (NSE:GRANULES) Business Description

Traded in Other Exchanges
Address
3rd Block, My Home Hub, 2nd Floor, Madhapur, Hyderabad, TG, IND, 500 081
Granules India Ltd is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates and finished dosages. Its business is organized into three areas; the Core business which comprises core molecules such as Paracetamol, Ibuprofen, Metformin, Guaifenesin, and Methocarbamol; the Emerging business that focuses on manufacturing APIs and the US Generics. It has one segment Pharmaceutical products including ingredients and intermediaries. Its primary geographic markets are North America, Latin America, Europe, India, and Rest of World.

Granules India (NSE:GRANULES) Headlines

No Headlines